Compare Sana Biotechnology Inc (SANA) vs US Bancorp (USB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sana Biotechnology Inc vs US Bancorp — how do they compare? Sana Biotechnology Inc trades at $3.78 (market cap $1.13B), while US Bancorp trades at $64.34 (market cap $100.17B). The key difference: US Bancorp is far larger — about 88.6× Sana Biotechnology Inc's market cap, and US Bancorp pays a 3.24% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals.
| SANA | USB | |
|---|---|---|
Market Cap | $1.13B | $100.17B |
Sector | Health | Financials |
52-Week High | $5.92 | $64.47 |
52-Week Low | $2.68 | $45.28 |
Enterprise Value | $1.05B | — |
Dividend Yield | — | 3.24% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
U.S. Bancorp (USB) trades at $64.19, up 0.39% today, with a bullish technical outlook and strong fundamental performance. The stock has consistently beaten earnings estimates in recent quarters, with Q2 2026 EPS of $1.35 surpassing the $1.28 expectation. Revenue and net income have shown steady growth, with 2025 revenue at $28.54 billion and net income at $7.57 billion. Analyst sentiment is positive, with a consensus price target of $70.27, indicating potential upside.
The outlook for USB is favorable, supported by robust earnings growth, a solid dividend, and positive analyst ratings. Key risks include exposure to interest rate fluctuations and macroeconomic volatility, as highlighted by recent news on potential Fed rate hikes. Institutional investors have been increasing stakes, reinforcing confidence. The stock presents a compelling opportunity for value-oriented investors seeking steady returns amid a stable banking sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →About US Bancorp
As a diversified financial-services provider, U.S. Bancorp is one of the nation's largest regional banks, with branches in well over 20 states, primarily in the Western and Midwestern United States. The bank offers many services, including retail banking, commercial banking, trust and wealth services, credit cards, mortgages, and other payments capabilities.
Read more on USB →
